Early, intermediate and advanced Hodgkin's lymphoma: modern treatment strategies

被引：17

作者：

Diehl, V. ^{[1
]}

Fuchs, M. ^{[1
]}

机构：

[1] Univ Cologne, D-5000 Cologne 41, Germany

来源：

ANNALS OF ONCOLOGY | 2007年 / 18卷

关键词：

D O I：

10.1093/annonc/mdm297

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：71 / 79

页数：9

共 22 条

[1] Involved-field radiotherapy for advanced Hodgkin's lymphoma [J].

Aleman, BMP ;

Raemaekers, JMM ;

Tirelli, U ;

Bortolus, R ;

van't Veer, MB ;

Lybeert, MLM ;

Keuning, JJ ;

Carde, P ;

Girinsky, T ;

van der Maazen, RWM ;

Tomsic, R ;

Vovk, M ;

van Hoof, A ;

Demeestere, G ;

Lugtenburg, PJ ;

Thomas, J ;

Schroyens, W ;

De Boeck, K ;

Baars, JW ;

Kluin-Nelemans, JC ;

Carrie, C ;

Aoudjhane, M ;

Bron, D ;

Eghbali, H ;

Smit, WGJM ;

Meerwaldt, JH ;

Hagenbeek, A ;

Pinna, A ;

Henry-Amar, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2396-2406

[2]

BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO

[3]

2-7

[4] Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease [J].

Diehl, V ;

Franklin, J ;

Pfreundschuh, M ;

Lathan, B ;

Paulus, U ;

Hasenclever, D ;

Tesch, H ;

Herrmann, R ;

Dörken, B ;

Müller-Hermelink, H ;

Dühmke, E ;

Loeffler, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) :2386-2395

[5]

DIEHL V, 2004, BLOOD, V104, pA307

[6] Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial [J].

Duggan, DB ;

Petroni, GR ;

Johnson, JL ;

Glick, JH ;

Fisher, RI ;

Connors, JM ;

Canellos, GP ;

Peterson, BA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :607-614

[7] Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma:: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group [J].

Engert, A ;

Schiller, P ;

Josting, A ;

Herrmann, R ;

Koch, P ;

Sieber, M ;

Boissevain, F ;

de Wit, M ;

Mezger, J ;

Dühmke, E ;

Willich, N ;

Müller, RP ;

Schmidt, BF ;

Renner, H ;

Müller-Hermelink, HK ;

Pfistner, B ;

Wolf, J ;

Hasenclever, D ;

Löffler, M ;

Diehl, V .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) :3601-3608

[8]

Fermé C, 2000, BLOOD, V96, p576A

[9] MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the Intergroup trial [J].

Glick, JH ;

Young, ML ;

Harrington, D ;

Schilsky, RL ;

Beck, T ;

Neiman, R ;

Fisher, RI ;

Peterson, BA ;

Oken, MM .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :19-26

[10] ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi [J].

Gobbi, PG ;

Levis, A ;

Chisesi, T ;

Broglia, C ;

Vitolo, U ;

Stelitano, C ;

Pavone, V ;

Cavanna, L ;

Santini, G ;

Merli, F ;

Liberati, M ;

Baldini, L ;

Deliliers, GL ;

Angelucci, E ;

Bordonaro, R ;

Federico, M .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9198-9207

← 1 2 3 →